Aberrant Expression of EZH2 in Pediatric Patients with Myelodysplastic Syndrome: A Potential Biomarker of Leukemic Evolution

Table 3

Association of EZH2 gene expression with clinical features, karyotypes and leukemic evolution in pediatric patients with primary MDS.

Parameter	EZH2 gene expression (median)		value
Age of patients
< 12 years old (children),	1.8
> 12 years old (adolescents),	2.7
Pediatric patients ()	1.8
Pediatric healthy individuals ()	1.15
MDS subtypes
Initial stage (RCC) ()	1.7
Advanced stages (RAEB/RAEB-t) ()	2.9
Karyotypes
Normal ()	1.7
Abnormal ()	1.8
Specific chromosomal pattern
Normal karyotypes ()	1.7
−7 and del(7q) ()	0.2
+8 ()	5.96
del(11q) ()	6.35
Levels of EZH2 expression
Low ()	0.2
Intermediate ()	1.61
High ()	4.81
Donors versus levels of EZH2 expression (groups)	Donors	Groups
Donors () vs. Low expression patients ()	1.15	0.2
Donors () vs. Intermediate expression patients ()	1.15	1.61
Donors () vs. High expression patients ()	1.15	4.81
	Low (8/8)
Evolution of disease (MDS →AML) versus levels of EZH2 expression	Intermediate (1/23)
	High (7/11)
Evolution of disease (MDS →AML) versus levels of EZH2 expression	Low (8/8)
	High (7/11)